在心力衰竭患者中进行巴罗反射激活疗法,心脏衰竭患者的排气分数减少
Jean M Ruddy1, Anne Kroman2, Catalin F Baicu2
1Division of Vascular Surgery, Department of Surgery, Medical University of South Carolina, 30 Courtenay Drive, Charleston, SC 29425, USA; Ralph H Johnson Department of Veterans Affairs Health Care System, 109 Bee Street, Charleston, SC 29401, USA.
Heart failure clinics
|November 12, 2023
概括
巴罗反射激活疗法 (BAT) 对心力衰竭患者是安全的. 在最近的一项临床试验中,这种治疗改善了症状,运动能力和生活质量.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭管理的管理
背景情况:
- 减少喷射率 (HFrEF) 的心力衰竭显著影响患者的生活质量和运动能力.
- 目前的指南导向医疗管理 (GDMM) 可能无法充分缓解所有HFrEF患者的症状.
- 对于解决HFrEF持续症状的创新疗法的需求至关重要.
研究的目的:
- 评估巴罗反射激活疗法 (BAT) 的安全性和有效性,用于症状HFrEF的患者.
- 评估 BAT 对以患者为中心的结果的影响,包括运动能力和生活质量.
- 确定 BAT 对相关生物标记物的影响,例如 n-终端亲B型尿酸 (NT-proBNP).
主要方法:
- 使用随机对照试验设计来评估巴罗反射激活疗法 (BAT).
- 参与者包括患有HFrEF,纽约心脏协会II/III类,LVEF≤35%,NT-proBNP升高的患者.
- 排除标准包括接受心脏再同步治疗的患者.
主要成果:
- 巴罗反射激活疗法 (BAT) 在研究的HFrEF人群中被证明是安全的.
- 在以患者为中心的症状结局中观察到显著改善.
- 关键的改进包括增加运动能力,提高生活质量,降低NT-proBNP水平和更好的功能类.
结论:
- 巴罗反射激活疗法 (BAT) 是选择性症状HFrEF患者的一种安全有效的治疗选择.
- 在心力衰竭中,BAT为症状管理,功能状态和生活质量提供了显著的好处.
- 美国食品和药物管理局的批准支持BAT作为治疗耐火HFrEF症状的治疗武器库的宝贵补充.
更多相关视频
09:56Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
Published on: February 14, 2021
5.1K
06:30Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
Published on: May 19, 2022
6.0K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
01:22Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:25Aortic Regurgitation III: Medical Management
24
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
24